Roots Analysis
JANUARY 23, 2024
Owing to the challenges involved in the synthesis process and demands of modern drug development, majority of drug developers in this domain prefer to outsource their development and manufacturing operations to peptide therapeutics contract API manufacturers as a strategic solution to streamline their research and peptide synthesis efforts.
The Pharma Data
AUGUST 20, 2020
DEVELOP A UNIFIED SCIENTIFIC VOICE. The latest results underscore that large pharma companies are making a “strategic retreat from some of their older drugs,” in China, ICBC International Research analyst Zhang Jialin said, as quoted by Bloomberg; instead, they’re focusing on growing market share for newer medicines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ACRP blog
NOVEMBER 8, 2023
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
ACRP blog
NOVEMBER 8, 2023
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
XTalks
APRIL 13, 2021
Even though plant-based milk is the most developed category, it still grew 20 percent in dollar sales, up five percent from 2019. Kyle Gaan, a research analyst at GFI said in the same press release, “2020 was a breakout year for plant-based foods across the store. of the $7 billion market.
The Pharma Data
DECEMBER 31, 2020
where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. Reimer replaces Charlotte Russel and will be responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies.
The Pharma Data
DECEMBER 28, 2020
Prior to that, Dr. Zhang was an equity research analyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine. .”
Expert insights. Personalized for you.
40 
Let's personalize your content